



Press Release

Tuesday, November 1, 2016

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval For Abacavir Tablets

Product to be launched immediately

Bangalore, November 1, 2016 Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Abacavir Tablets USP, 300 mg**

According to IMS data, the US market for Abacavir is approximately USD 30 Million.

The product will be manufactured at the Company's USFDA approved facility at Bangalore and marketed by Strides in the US Market. The product will be launched immediately.

About Abacavir

Abacavir Tablets is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents

About Strides Shasun Limited

Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 13 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<u>Strides Shasun</u> Badree Komandur, Group CFO +91 80 6784 0747 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
---	--